Lynn Welter

University of Luxembourg, Life Sciences Research Unit

Luxembourg

Project

The impact of PPAR signaling on Alzheimer's disease

Summary

Epidemiological studies have demonstrated that long-term intake of non-steroidal anti-inflammatory drugs (NSAIDs) decrease the risk for developing Alzheimer's disease (AD). However, the mechanism behind these NSAIDs is still controversial. A subset of NSAIDs activate the peroxisome proliferator-activated receptor-g (PPARg). PPARg is a ligand-activated transcription factor that belongs to the superfamily of nuclear receptors. The activation of PPARg has been associated with potent anti-inflammatory as well as anti-amyloidogenic effects in cell culture and AD animal models. Unfortunately, very little is known about the molecular mechanisms that subserve these effects. Our team tries to identify and characterize primary PPAR target genes in microglia and neuronal cells which we think is important for the development of new therapeutic strategies and targets for the treatment of AD.

Posters

For the latest project poster please see the Documents below

Keep reading in this section...

• Yvonne Brehmer
• Bérengère Davin
• Hans-Joerg Ehni
• Antje Heinrich
• Anna Marie Herghelegiu
• Dietmar Herndler-Brandstetter
• Sarah Ehses
• Marko Kervinen
• Julia Kiyan
• Anastasia Meidani
• Chengxuan Qui
• Katarzyna Rubel
• Blossom Stephan
• Kristina Tiainen
• Sandra Torres
• Birgit Trukeschitz
• Jochen Zeigelmann
• Ulrike Waginger
• Marko Korhonen
• Fredrica Nyqvist
• Nicolas Sirven
• Gitit Lavy Shahaf
• Henna Hasson
• Anna Dahl
• Anja Leist
• Ana-Mara Buga
• Monika von Bonsdorff
• Mirka Rauniomaa
• Ulpukka Isopahkala-Bouret
• Petra Grönholm-Nyman
• Jenni Kulmala
• Kathrin Komp